Drug Policy

State AGs Are Doing Work on Drug Pricing

Erin Fuse Brown writes about a new article highlighting the role of state attorneys general on improving drug price affordability.

Read More

Let’s Make a Deal…on Drug Prices

Democrats are on the brink of passing a historic set of drug price reforms. How will they impact patients, insurers and the drug industry?

Read More

Can Democrats Reconcile Their Health Policy Differences?

Democratic lawmakers face tough health care compromises as they struggle to secure votes for their blockbuster spending bill.

Read More

The Aducanumab Aftermath: The Industry

How is the pharmaceutical industry reacting to the FDA’s surprising approval of a controversial Alzheimer’s drug?

Read More

The Aducanumab Aftermath: The Payer

A costly new Alzheimer’s drug could wreak financial havoc on insurers, seniors and taxpayers.

Read More

The Aducanumab Aftermath: The Patient

One patient shares her hopes and concerns about a costly new Alzheimer’s drug.

Read More

The Aducanumab Aftermath

The Aducanumab Aftermath A SPECIAL CONVERSATION SERIES June 22, 2021 Art by Leslie Walker About this Special Series The U.S. Food and Drug Administration (FDA) recently approved the costly new Alzheimer’s drug aducanumab (now known by the brand name Aduhelm) despite doubts about its safety and efficacy. Priced at $56,000 by drugmaker Biogen, aducanumab could…

Read More

The Aducanumab Aftermath: The Doctor

One doctor grapples with questions about a controversial new Alzheimer’s drug’s safety and efficacy.

Read More

The FDA’s Pressure-Packed Alzheimer’s Drug Decision

The FDA weighs whether to approve a controversial new Alzheimer’s drug.

Read More

Preventing HIV Just Got A Lot Cheaper. What Took So Long?

After nearly a decade of sky-high prices, new generics have sent the price of the HIV prevention drug PrEP plummeting.

Read More